Phase 2 N=26 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=44 Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer · Brain Cancer
Primary: Median Survival — 11.8 months
Phase 2 N=66 Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.4 Weeks
Phase 2 N=265 Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants
Phase 3 N=356 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 28.5; 25.3 months — p=0.2853
Phase 2 N=13 Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases
Non-small Cell Lung Cancer
Primary: Intracranial Objective Response Rate — 6; 0; 5; 0 Participants
Phase 2 N=307 Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
Brain Metastases From Non-small Cell Lung Cancer
Primary: Overall Survival — 185; 209; 209 days — p=0.933
Phase 2 N=115 A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Non-Small Cell Lung Cancer · Brain Neoplasms
Primary: Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System…
Phase 2 N=41 Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Melanoma · Non-small Cell Lung Cancer · Brain Metastasis
Primary: Brain Metastasis Response Rate (BMRR) — 54.1; 75 percentage of participants
Phase 2 N=65 MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Melanoma · Non-Small Cell Lung Cancer · Brain Metastases
Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants
Phase 1 N=25 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Metastatic Malignant Neoplasm in the Brain · Metastatic Melanoma · Mucosal Melanoma
Primary: Dose Limiting Toxicities — 0; 0; 0 Participants
Phase 2 N=40 Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
Non-small Cell Lung Cancer Stage IV
Primary: Efficacy of Atezolizumab + CBDCA + Pemetrexed by Evaluating PFS Rate — 62.2 percentage of participants
N/A N=35 Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Phase 2 N=91 A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months — 56.5; 57.2 percentage of participants
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
Phase 2 N=30 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Phase 2 N=36 Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Non-Small Cell Lung Cancer · Leptomeningeal Metastases · Brain Metastases
Primary: Best Overall Response Rate (ORR) of Subjects With BM — 15.4; 100; 31.3; 0 Percentage of participants (%)
Phase 2 N=97 Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Phase 2 N=27 Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Stage IV Non-small Cell Lung Cancer (NSCLC) · Recurrent Non-small Cell Lung Cancer (NSCLC) · Extensive-stage Small Cell Lung Cancer (SCLC)
Primary: Central Nervous System (CNS) Disease Control Rate (Cohort A and C) — 2; 2 Participants
N/A N=215 BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium
Stage IV Non-small Cell Lung Cancer
Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 3 N=393 Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Carcinoma · Limited Stage Small Cell Lung Carcinoma
Primary: Number of Participants With Deterioration in HVLT-R Delayed Recall Score at Six Months (Phase III) — 33; 27 Participants — p=0.28
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
Phase 2 N=60 Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Phase 2 N=29 Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial
Stage IV Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 3.5; 9.7 months — p=.01
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants